Schizophrenia / Edition 2

Schizophrenia / Edition 2

by Mario Maj
     
 

ISBN-10: 0470849649

ISBN-13: 9780470849644

Pub. Date: 02/24/2003

Publisher: Wiley, John & Sons, Incorporated

Be Guided by the Evidence...

In this new edition of the second volume in the WPA Series, Evidence and Experience in Psychiatry, focuses on the controversial issues surrounding schizophrenia. By using systematic reviews with accompanying commentaries this volume is able to assess the ?evidence? and ?experience? to give a critical and objective account of the relevant

Overview

Be Guided by the Evidence...

In this new edition of the second volume in the WPA Series, Evidence and Experience in Psychiatry, focuses on the controversial issues surrounding schizophrenia. By using systematic reviews with accompanying commentaries this volume is able to assess the ?evidence? and ?experience? to give a critical and objective account of the relevant issues, while focusing on key topics, such as diagnosis and prevention of disability and stigma.

This revised and updated volume provides:

  • The best available evidence to enable well-informed clinical decision making
  • Valuable insights from some of the world?s leading experts in the field of schizophrenia
  • Coherent description and discussion of the relevant issues
This new edition will be a vital source of information for psychiatrists, psychologists, mental health nurses, managers and policy makers.

Product Details

ISBN-13:
9780470849644
Publisher:
Wiley, John & Sons, Incorporated
Publication date:
02/24/2003
Series:
WPA Series in Evidence & Experience in Psychiatry Series, #11
Edition description:
REV
Pages:
514
Product dimensions:
6.00(w) x 9.33(h) x 1.11(d)

Table of Contents

List of Review Contributorsxiii
Prefacexv
Chapter 1Diagnosis of Schizophrenia1
Diagnosis of Schizophrenia: A Review1
Commentaries
1.1The Diagnosis of Schizophrenia: Practice and Concept38
1.2Should Schizophrenia as a Disease Entity Concept Survive into the Third Millennium?40
1.3On Defining Schizophrenia43
1.4Diagnosis and Pathophysiology of Schizophrenia45
1.5The Significance of Intuition for the Diagnosis of Schizophrenia47
1.6Heterogeneity vs. Homogeneity in Operationally-diagnosed Schizophrenia50
1.7Diagnosis of Schizophrenia: Arguments for a Narrowing of the Concept52
1.8Schizophrenia: A Provisional Diagnostic Convention55
1.9Diagnosing Schizophrenia: A Personal View58
1.10Comments on the Diagnosis of the Schizophrenic Syndrome60
1.11The Schizophrenic Syndrome: A Warning and a Conjecture62
1.12A Century of Schizophrenia is Enough65
1.13Diagnosis of Schizophrenia: A View from Developing Countries68
1.14Studies on Schizophrenic Symptomatology in Peru70
1.15Neuropsychological and Psychophysiological Contributions to the Diagnosis of Schizophrenia72
Chapter 2Pharmacological Treatment of Schizophrenia75
Pharmacological Treatment of Schizophrenia: A Review75
Commentaries
2.1Pharmacotherapy of Psychotic Disorders: A Perspective on Current Developments114
2.2Pharmacotherapy of Schizophrenia: Gaps in our Knowledge118
2.3Atypical Antipsychotic Drugs and Schizophrenia120
2.4Compliance Issues and the New Antipsychotics122
2.5Schizophrenia and Second-generation Antipsychotics: Mechanistic Implications and Potential for Early Intervention125
2.6Dose and Duration of Antipsychotic Treatment: Key Variables, Critical Uncertainties128
2.7Dosing Problems of Classical Neuroleptics and the Relevance of Novel/Atypical Antipsychotics in the Pharmacotherapy of Schizophrenic Disorders130
2.8Can We Use Pharmacotherapy More Logically in Schizophrenia and Other Psychoses?133
2.9Long-term Treatment in Schizophrenia: For Whom and How Long?135
2.10Novel Antipsychotics in Schizophrenia and Related Disorders: Preliminary Findings from a First-episode Study137
2.11The Pharmacotherapy of Schizophrenia in Clinical Practice140
2.12A New Era of Hope in Treating Persons with Schizophrenia141
2.13New Perspectives in Antipsychotic Pharmacotherapy143
2.14Some Aspects of the Maintenance Treatment of Schizophrenia146
2.15Highlights on the Management of Schizophrenia148
2.16Pharmacotherapy of Schizophrenia: The Case of Developing Countries150
Chapter 3Psychotherapies for Schizophrenia153
Psychotherapies for Schizophrenia: A Review153
Commentaries
3.1Relevant Methods, Goals, Time-dimensions and Emotional Influences in the Psychotherapy of Schizophrenia221
3.2Family and Individual Cognitive-Behavioural Interventions223
3.3It is no Longer Surprising that Cognitive-Behavioural Therapy Reduces Distressing Psychotic Symptoms226
3.4Serious Questions Remain Concerning Efficacy, Effectiveness and Scope of Family Interventions in Schizophrenia228
3.5The Interaction of Psychotherapy and Drugs in the Management of Schizophrenia: A Neglected Field230
3.6How Effective are Psychotherapies for Schizophrenia?232
3.7Need for an Integrated and Need-adapted Approach in Treating Schizophrenia235
3.8To Integrate the Psychotherapy of Schizophrenia into the Activities of the Multidisciplinary Team, and to Base it on the Principles of Evolutionary Biology237
3.9Psychotherapy for Schizophrenia: An Important Addition to Medication Alone?239
3.10The Effectiveness of Cognitive-Behavioural Therapy in Schizophrenia242
3.11Family: A System Which Cannot Be Neglected244
3.12Psychological Interventions for Schizophrenia in Developing Countries246
Chapter 4Prevention of Disability and Stigma Related to Schizophrenia249
Prevention of Disability and Stigma Related to Schizophrenia: A Review249
Commentaries
4.1What Works for the Rehabilitation of Schizophrenia? A Brief Review of the Evidence285
4.2The Stigma of Mental Illness: Some Empirical Findings287
4.3Reducing the Stigma Associated with Schizophrenia290
4.4The Influence of Stigma on Preventive Efforts in Psychotic Disorders292
4.5Disability, Stigma and Discrimination: A View from Outside the USA294
4.6The Toxic Effects of Stigma297
4.7The Conceptualization of Long-term, Disabling Psychiatric Disorders299
4.8Utility of Multiaxial Assessment in the Rehabilitative Work with Chronically Disturbed Patients301
4.9"Clanning" for Recovery303
4.10Stigma and Schizophrenia: The Greek Experience306
4.11Disability and Stigma Prevention: The Russian Experience308
4.12Are Western Models of Psychiatric Rehabilitation Feasible and Appropriate for Developing Countries?310
4.13Is Schizophrenia a Chronic Illness? The Experience of Developing Countries313
4.14Prevention of Disability and Stigma: Experience from a Developing Country314
Chapter 5Schizophrenia Spectrum Disorders317
Schizophrenia Spectrum Disorders: A Review317
Commentaries
5.1Extending the Schizophrenia Spectrum even Further378
5.2Schizotypy: Theoretical Considerations, Latent Structure, and the Expanded Phenotype380
5.3Empirical Characterization of the Schizophrenia Spectrum383
5.4Exploring Schizophrenia Across the Continuum385
5.5Schizophrenia Spectrum Disorders and the Psychotic Continuum387
5.6Dimensions of Schizotypy in Symptomatic, Neurocognitive and Psychophysiological Indicators390
5.7The Role of Syndromes and Neurophysiology in Conceptualizing the Schizophrenia Spectrum and Predisposing Influences392
5.8Irremediable Flaws in the Schizophrenia Spectrum Concept395
5.9Do Not Dismiss the Single Major Locus Hypothesis So Quickly398
5.10Schizophrenia Spectrum: Where to Draw the Boundary?401
5.11Is There a Place for the Nature-Nurture Hypothesis in the Aetiology of Schizophrenia Spectrum Disorders?404
5.12Schizophrenia Spectrum--a "Terra Flexibilis"406
5.13Some Open Research Issues Concerning Schizophrenia Spectrum Disorders408
5.14Schizophrenia Spectrum Disorders Revisited409
Chapter 6Economics of Schizophrenia413
Economics of Schizophrenia: A Review413
Commentaries
6.1Is Schizophrenia Worth the Cost?461
6.2Morality and Cost in the Management of Schizophrenia464
6.3Caveat Emptor: Pitfalls in Measuring the Costs of Schizophrenia466
6.4The Economic Consequences of Schizophrenia468
6.5The Many and the Few: Evidence-based Mental Health in a Primary-care-led Health Service470
6.6The Long-term Course of Schizophrenia and its Economic Consequences472
6.7Health Economics in Schizophrenia: Clouding or Clarifying?474
6.8The Economic Burden of Schizophrenia477
6.9Lack of Comprehensive Care for Schizophrenic Patients: Is it Due to Prohibitive Costs or Insufficient Advocacy?478
6.10The Role of Cost-effectiveness Analysis in Improving the Treatment of Schizophrenia481
6.11Medical Cost Outcomes of the Atypical Antipsychotics483
6.12The Costs of Schizophrenia--New Treatments and New Economics486
Acknowledgements for the First Edition489
Index491

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >